Levothyroxine Use in the United States, 2008-2018

Abstract

This cross-sectional study assesses national data for commercially insured and Medicare Advantage enrollees to analyze the use of levothyroxine in the US over time.

Conflict of interest statement

Conflict of Interest Disclosures: Dr Ross reported grants from the US Food and Drug Administration, Johnson & Johnson, Medical Device Innovation Consortium, Agency for Healthcare Research and Quality (R01HS022882), National Institutes of Health/National Heart, Lung, and Blood Institute (R01HS025164), and the Laura and John Arnold Foundation outside the submitted work. Dr Shah reported receiving research support through Mayo Clinic from the US Food and Drug Administration to establish Yale University–Mayo Clinic Center of Excellence in Regulatory Science and Innovation program (U01FD005938); the Center for Medicare & Medicaid Innovation under the Transforming Clinical Practice Initiative; the Agency for Healthcare Research and Quality (R01HS025164; R01HS025402; R03HS025517; K12HS026379); the National Heart, Lung and Blood Institute of the National Institutes of Health (R56HL130496; R01HL131535; R01HL151662); the National Science Foundation; the Medical Device Innovation Consortium as part of the National Evaluation System for Health Technology; and the Patient-Centered Outcomes Research Institute to develop a Clinical Data Research Network (LHSNet). Dr Lipska reported grants from the National Institute of Diabetes and Digestive and Kidney Diseases and Patient-Centered Outcomes Research Institute and support to develop and evaluate publicly reported quality measures from Centers for Medicare & Medicaid Services outside the submitted work. No other disclosures were reported.

Figures

Figure.. Trend of Levothyroxine Use Between 2008 and 2018 by Thyroid Function Categories

T4 indicates thyroxine.